Market quick glance | The three major Indices showed mixed results, with the tech index slightly rising, Xiaomi and Tencent increasing nearly 3%; Semiconductors stocks were strong, with Semiconductor Manufacturing International Corporation rising over 8%;

Network Technology stocks performed poorly, KUAISHOU-W fell by 5.42%, Alibaba-W dropped by 3.44%; most Coal Industrial Concept stocks declined, SOUTHGOBI fell by 12.02%, China Coal Energy dropped by 6.37%; many Hong Kong Retail Stocks fell, PRADA decreased by 3.80%, BOSSINI INT'L dropped by 3.48%;

Futu NewsDec 20 16:23

Citi raised the Target Price for HANSOH PHARMA (03692.HK) to 25.24 yuan with a rating of 'Buy'.

CMB International released a report stating that HANSOH PHARMA (03692.HK) has granted MSD global exclusive rights for its preclinical oral small molecule GLP-1 receptor agonist HS-10535. HANSOH will receive a prepayment of 0.112 billion USD and may receive milestone payments of up to 1.9 billion USD, as well as future sales royalties. CMB International believes that, aside from weight loss effects, the safety of small molecule GLP-1 drugs is a key differentiating factor. The rating for this stock is maintained at 'Buy', believing that HANSOH has successfully developed a comprehensive GLP-1 Assets pipeline portfolio, and the collaboration with MSD will...

AASTOCKSDec 20 14:57

Zhuhai International: Maintains HANSOH PHARMA (03692) "Buy" rating with the Target Price raised to HKD 25.24.

HANSOH PHARMA has granted MSD the global exclusive license for its preclinical oral small molecule GLP-1 receptor agonist HS-10535.

Zhitong FinanceDec 20 14:45

Bank of America Securities: Reiterates Buy rating for INNOVENT BIO (01801) and HANSOH PHARMA (03692) with both Target Prices raised.

INNOVENT BIO (01801) recently reached a commercialization agreement with Eli Lilly and Co (LLY.US) for its non-covalent (reversible) BTK inhibitor "Jepalibri" in mainland China.

Zhitong FinanceDec 20 11:47 · Ratings

Hansoh Pharmaceutical Units Sign Up to $2 Billion Licensing Deal for Weight Loss Drug Candidate

MT NewswiresDec 20 10:57

Bank of America Merrill Lynch has lowered the Target Price for Shanghai Pharmaceuticals (01093.HK) to 4.6 yuan and raised the Target Price for INNOVENT BIO (01801.HK) to 56.4 yuan.

Merrill Lynch Securities released a Research Report stating that CSPC PHARMA (01093.HK) and BEIGENE (06160.HK) have reached a global exclusive licensing agreement for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor SYH2039 and subsequent development. Taking into account the aforementioned collaboration and the recent bidding results of the tenth batch of national organization pharmaceutical centralized procurement, the revenue forecasts for CSPC PHARMA for 2024 to 2026 have been adjusted down by 0.8%, up by 1.7%, and down by 1.7%, respectively, while the earnings per share forecasts have been adjusted down by 0.9%, up by 10.5%, and down by 1.9%. Considering CSPC PHARMA's core product Enbrel.

AASTOCKSDec 20 09:44